

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-455US1	Application No. To Be Assigned
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Judith McNally et al.	
		Filing Date Herewith	Group Art Unit

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
---------------------	--------------	--------------------	---------------------	----------	-------	----------	-------------------------------

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Translation	
							Yes	No
	1	WO01/09110	02/08/2001	Boehringer Ingelheim Pharmaceuticals, Inc.				
	2	WO01/49288	07/12/2001	Merck Frost Canada & Co. and Axys Pharmaceuticals, Inc.				
	3	WO03/048123	06/12/2003	F. Hoffmann-LA Roche AG				
	4	WO2004/056324	07/08/2004	Bristol-Myers Squibb Company				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	5	CAI et al. "Cathepsin K Inhibitors 2000-2004" Expert Opinion Ther. Patents. 2005 (15) 33-48
	6	
	7	
	8	
	9	
	10	
	11	
	12	
	13	
	14	
	15	
	16	
	17	
	18	
	19	

Examiner Signature /Rebecca Anderson/	Date Considered 06/12/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RA/